The difference between you and I is that I have done the
The difference between you and I is that I have done the proper research from the beginning of Covid and followed the medical testing and ALL the drugs thought to help with Covid…what was approved and what was not. Many drugs showed promise but didn’t pan out. I followed all the clinical trial papers submitted by the trial scientist that were trying to help our people and learned a great deal in the process.
The most important things I learned were from virologists and the consensus of what the experts were. Maybe you don’t know what a virologist is? Let me explain just what their life work is. Virologists are doctors that study viruses and they know biologically how the viruses work and travel into our systems how they hide in our cells at the cellular level and what will remove them or expose them so our immune system or a drug can try to deal with them.
So when you look up any research about the vaccine or just Covid itself. If is doesn’t have a virologist delivering the information or referenced as a source of the information. You might want to throw that information away. Because religion won’t help you. Neither will web sites that are not informed by medical experts. The medical experts here are virologists and they are usually PHD’s that study their whole life just how each and every virus works. Covid now included. There are many papers written about their findings. They make recommendations also. These are the important recommendations.
You can learn a whole lot from clinicaltrials.gov Just search “ Covid “ and read about the trials that have been preformed and what some drugs did and what the results were. If you so choose to start your quest for the true knowledge and not what he said / she said… type of information that is worthless. Just know that I have done this all along and I am two years or more ahead of you.
With proper facts we make wise decisions. You first have to know where to find the true facts. From the people that know the true facts. The experts… in this case the experts are virologists.
1
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...
Continue Reading
Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...
Continue Reading
Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...
Continue Reading
The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...
Continue Reading
Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...
Continue Reading
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....
Continue Reading
The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...
Continue Reading
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
Top 5 Most Recently Viewed Articles
Velcan Holdings Expands Share Buyback Initiative Velcan Holdings has been actively engaged in a strategic share buyback program, reflecting its commitment to enhance shareholder value. This initiative, governed by a resolution from a shareholders’ meeting, aims to repurchase shares in the market to consolidate the company’s financial stability and improve its stock's...
Continue Reading
Introduction to the Glycolic Acid Market The Glycolic Acid Market is on a path of significant growth, positioning itself as a key player largely influenced by its rising applications in the cosmetic and industrial sectors. This alpha hydroxy acid (AHA) is cherished for its efficacy in skincare, particularly in products such as exfoliants and chemical peels, where it helps...
Continue Reading
World Bank's Major Financial Support for Argentina The World Bank is stepping up its support for Argentina by injecting over $2 billion in new loans. This significant financial assistance is targeted toward vital sectors including social security, education, transportation, and energy. The aim is to tackle pressing issues such as poverty within the nation. Details from...
Continue Reading
Unveiling Nu Holdings: Brazil's Fintech Beacon As the final weeks of the first quarter approach, an intriguing shift is evident in the financial landscape. While the benchmark S&P 500 shows less agility compared to numerous foreign markets, Latin American firms stand out as promising investments. This presents an enticing opportunity for those investors looking to...
Continue Reading
Understanding NVIDIA's Market Position In today's fast-paced and highly competitive business environment, investors must evaluate companies closely. This article examines NVIDIA (NASDAQ: NVDA) in depth, providing insights for investors by analyzing its performance against major competitors in the Semiconductors & Semiconductor Equipment sector. By delving into essential...
Continue Reading